Hydrogenology
Hydrogenology editorial study record

The effects of hydrogen treatment in a cigarette smoke solution-induced chronic obstructive pulmonary disease-like changes in an animal model

Yang HJ, Tsou WH, Shen MC, Liu CY, Saunders HM, Wang KY, Douglas FL. · Journal of thoracic disease. 2022;14(11):4246-4255.

PreclinicalInhaled H₂Published 2022
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled preclinical study

Research topic

Respiratory health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

mice, mouse, cell used to study respiratory health.

Sample

Preclinical study; group or assay counts reported in the full text include n=8, n=10, n=12, n=6, n=4.

Duration

0.9 L/min

Intervention

Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 42%, 21%, 43%, 0.9 L/min, 75 minutes, 63 days.

Hydrogen form

Inhaled molecular H₂ at 42%; oxygen co-delivery is reported.

H₂ specification

H₂-related quantities reported in the intervention passages: 42%, 21%, 43%, 0.9 L/min, 75 minutes, 63 days. Values are not combined across different experimental arms.

H₂ flow

378 mL/min H₂, calculated from 42% H₂ and 900 mL/min total flow reported in the full text.

O₂ delivered with H₂

21% O₂; 189 mL/min O₂ calculated from the reported total flow.

Comparator

Control or comparison condition reported in the full article; see the linked methods for arm-specific details.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

survival or mortality, clinical symptoms or functional scores, oxidative-stress and antioxidant markers, apoptosis or cell injury, respiratory measures

Reported result

Article-reported result excerpt (24 words maximum): “The MLI of the lung in the COPD + H_2/O_2 group (36.254±7.487) was significantly decreased compared to the COPD group (52.068±16.473) (P<0.05, [ Figure…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Results-extraction completeness

The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical evidence only; findings do not establish a treatment effect in people. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Applies directly to

Applies to the reported animal, cell or tissue model, not directly to patients.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 36524091 · DOI: 10.21037/jtd-22-324

Publisher access

A free full article is available through PubMed Central.

Extraction basis

Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.

Record revision

2026-08-10